News
Amref, Astrazeneca Build COVID-19 Mobile Clinics In Kenya
In an effort to shield last-mile communities from the pandemic, Amref Health Africa and AstraZeneca are introducing a fleet of Mobile Vaccination Clinics (MVCs) in partnership with the Ministry of Health (MoH) in Kenya. The ten mobile clinics will target...
News
US FDA Advisers Advocate Changing Fall COVID Vaccine Dosage
To address more recently circulating coronavirus strains, advisors to the U.S. Food and Drug Administration recently suggested altering the design of COVID-19 booster doses this fall. The next round of COVID booster shots should contain a component that combats the...
News
Novartis Will Cut 8,000 Jobs By 2024 To Save $1 Billion
As many as 8,000 employees could be eliminated by Novartis AG as part of a plan to improve the pharmaceutical behemoth's performance and save at least $1 billion by 2024. The Swiss company announced the restructure in April and...
News
What Is The Reason For A Sluggish African Immunisation Rate?
The World Health Organization (WHO) set a goal in October 2021 to fully immunise 70% of each nation's population against COVID-19 by the end of June 2022. Many Covid-19 vaccination programmes in developing countries, especially in Sub-Saharan Africa, were...
News
Australia Introduces A Fresh Outlook To Stem Cell Production
A novel 3D printed methodology for extracting stem cells from bioreactors has been created by researchers at the University of Technology, Sydney, opening the door to the possibility of high-quality, mass-produced stem cells in Australia at a cheaper price.
Due...
News
Novartis Announces $250M Funding In R&D For NTDs, Malaria
Novartis has committed to investing $250 million in research and development over the next five years in an effort to find a cure for malaria and other neglected tropical diseases (NTDs). CEO Vas Narasimhan remarked in a statement that...
News
GSK Pledges £1 Billion R&D Commitment For The Poor Nations
In order to speed up research and development (R&D) for communicable diseases that disproportionately hurt lower-income nations, GSK plc announced a commitment of £1 billion over 10 years.
This research will focus on novel and ground-breaking vaccines and medications to diagnose...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read